Review
doi: 10.1016/s0002-9149(98)00256-2.
Guidelines for approval of anti-obesity drugs affecting atherosclerosis and/or lipids. The international union of pharmacology (IUPHAR)
Affiliations
- PMID: 9604902
- DOI: 10.1016/s0002-9149(98)00256-2
Item in Clipboard
Review
Guidelines for approval of anti-obesity drugs affecting atherosclerosis and/or lipids. The international union of pharmacology (IUPHAR)
Am J Cardiol.
.
No abstract available
Similar articles
-
Experimental drugs take aim at obesity.JAMA. 2003 Apr 9;289(14):1763-4. doi: 10.1001/jama.289.14.1763. JAMA. 2003. PMID: 12684341 No abstract available.
-
Anti-obesity drugs: to be or not to be?Obes Rev. 2010 Dec;11(12):833-4. doi: 10.1111/j.1467-789X.2010.00828.x. Epub 2010 Nov 3. Obes Rev. 2010. PMID: 21054758 No abstract available.
-
Two new drugs approved for obesity.S D Med. 2012 Sep;65(9):356-7. S D Med. 2012. PMID: 23066610 No abstract available.
-
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16. Expert Rev Cardiovasc Ther. 2010. PMID: 20707765 Review.
-
New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).Cardiol Rev. 2014 Jan-Feb;22(1):43-50. doi: 10.1097/CRD.0000000000000001. Cardiol Rev. 2014. PMID: 24304809 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
